- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01109654
An Observational Study of Cetrotide® Gonadotropin-releasing Hormone Antagonist (GnRH Antagonist) With GONAL-f® in Assisted Reproductive Technologies (ART)
A Prospective, Observational Study on the Use of Cetrotide (GnRH Antagonist) With GONAL-f in Assisted Reproductive Technologies (ART)
This is a multicentric, prospective, observational study on the use of Cetrotide to control the endogenous gonadotrophin levels in Gonal-f stimulated ART treatment cycles in the Asia-Pacific region. The study plans to enrol approximately 1800-2000 subjects over a 9-month period at each participating centre.
This observational study is initiated to collect information on the use of Cetrotide (GnRH antagonist) in ART cycles in routine practice across the Asia-Pacific region. The information will allow a better understanding of the current ovarian stimulation regimens that involve Cetrotide in the control of the endogenous gonadotrophin concentrations. The collection of live birth data, though a challenging task, as a secondary endpoint will allow the study to show valuable information on the final objective of ART. To minimize the potential variability due to the different ovarian stimulation agents, the study is to include cycles treated with Gonal-f (recombinant human FSH) since this agent is widely available in the region.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Gonadotrophin-releasing hormone (GnRH) antagonists were introduced in the beginning of this decade for the use in ART. The potential advantages of GnRH antagonists over the GnRH agonists include the avoidance of an acute stimulation of endogenous gonadotrophins and a dramatic reduction in the length of analogue treatment.
Despite the plus points of GnRH antagonists in ART, there has been some concern over the lower pregnancy rate reported, which may be the cause of a lower acceptance of GnRH antagonists in ovarian stimulation for in vitro fertilization (IVF). Interestingly, a separate meta-analysis did not reach the same finding. The probability of live birth after ovarian stimulation for IVF was found not to be dependent on the type of analogue used for pituitary suppression Cetrotide, a GnRH antagonist from Merck Serono, is currently approved for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation in majority of the regions. It is given either as a single-dose regimen of 3 mg injection or as a multiple-dose regimen of 0.25 mg daily injection. Both regimens have been shown to offer equivalent efficacy and safety outcomes.
OBJECTIVES:
Primary objective:
- To assess the effectiveness of Cetrotide regimens, when used with Gonal-f, in routine ART treatment cycles
Secondary objectives:
- To assess the effectiveness of Cetrotide regimens on other efficacy endpoints
- To survey the types of Cetrotide regimen used and their success rates
- To assess the safety of Cetrotide regimens
- To explore the association between subject characteristics and treatment outcomes
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 609927
- Singapore General Hospital Pte Ltd, Outram Road
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects who are undergoing ovarian stimulation for IVF or ICSI therapy
- Decision by treating physician to prescribe Gonal-f for controlled ovarian stimulation prior to study enrolment
- Decision by treating physician to prescribe Cetrotide as the down-regulation agent prior to study enrolment
Exclusion Criteria:
- Subjects using GnRH agonist as the down-regulation agent
- Contraindicated use of Cetrotide based on local label
- Subjects who have participated in the study previously
- Subjects with hypersensitivity to cetrorelix acetate, extrinsic peptide hormones or mannitol
- Subjects with known hypersensitivity to GnRH or any other GnRH analogs
- Subjects with known or suspected pregnancy, and lactation
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects achieving a clinical pregnancy.
Time Frame: At post hCG days 35-42
|
A transvaginal ultrasound scan will be performed on all subjects who become pregnant provided that no miscarriage has occurred.
|
At post hCG days 35-42
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with cancelled cycles
Time Frame: 3 month
|
3 month
|
|
Proportion of women with OHSS or risk of OHSS
Time Frame: 3 month
|
3 month
|
|
Duration and dose of Cetrotide administered
Time Frame: 3 month
|
3 month
|
|
Assessment of baseline characteristics
Time Frame: 3 month
|
Assessment of subjects age, weight, height, FSH and LH level prior to Gonal-f administration, concomitant treatment, infertility history and infertility treatment
|
3 month
|
Total dose of Gonal-f administered
Time Frame: 3 month
|
3 month
|
|
Duration of ovarian stimulation
Time Frame: 3 month
|
3 month
|
|
Number of oocytes retrieved
Time Frame: 3 month
|
3 month
|
|
Number of subjects with Adverse Events
Time Frame: 3 month
|
3 month
|
|
Pregnancy rate
Time Frame: 12 month
|
12 month
|
|
Live birth rate
Time Frame: 12 month
|
12 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Medical Director, Merck Pte. Ltd., Singapore
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EMR200088-500
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Istanbul University - Cerrahpasa (IUC)RecruitingInfertility | Sexual Dysfunction | Infertility, Male | Nurse's Role | Sexuality | Infertility; FemaleTurkey
Clinical Trials on Cetrorelix acetate and Follitropin alfa
-
Peking University Third HospitalRecruiting
-
Peking University Third HospitalNot yet recruitingInfertility, Female
-
Peking University Third HospitalRecruiting
-
IVFarma LLCInstitute for Preventive and Social MedicineCompletedFertility Issues | Fertility Disorders | IVF | Gynecologic Disease | Reproductive Issues | Reproductive DisorderRussian Federation
-
IVFarma LLCNADIM LLCCompletedPharmacokinetics | Absorption | Area Under CurveRussian Federation
-
Merckle GmbHCompleted
-
Northwest Women's and Children's Hospital, Xi'an...Not yet recruiting
-
Royan InstituteUnknown
-
IVFarma LLCBridgePharm LLC; GlobalPharma LLCCompletedInfertility, FemaleRussian Federation